6th Annual Future of Clinical Trials

Jacob Fleming Conferences26 - 27 October 2010, Vienna, Austria.
Leading Pharmaceutical players understand, how to complete trials with greater levels of cost-efficiency, timelines and success. Reveal, how to tailor clinical trials to the needs of the patients. Discuss the innovative methods of motivating patients and physicians. Learn from first hand experience, how to optimize patient recruitment & retention, and explore the patient pool in Russia and Southeastern Europe. Achieve the competitive advantage through increased partnering with academic centres of excellence, patient organizations and CROs.

Discuss with leading Pharma companies, what is the future of clinical trials & how to be prepared to succeed.

Key speakers:

  • Senior Vice President Global Clinical Operations, MerckSerono, Switzerland
  • Vice President Medical Affairs Global Diabetes Division, Sanofi Aventis, France
  • Deputy Head of Global Clinical Development Metabolism, Development Sub-Team Leader Dalcetrapib, Roche, Swizterland
  • VP R&D Science Policy, AstraZeneca, UK
  • Head Clinical Research, Novartis, Switzerland
  • Head Clinical Research, Novo Nordisk, Russia
  • Project Officer, VSOP, The Netherlands
  • Head of Biostatistics & Data Management, Global Clinical R&D, GSK Biologicals, Belgium
  • European AIDS Treatment Group (EATG), Germany
  • Chief Medical Officer Southern Europem, Novartis Vaccines & Diagnostics, Italy

Key topics:

  • New approaches to conducting clinical trials in a current dynamic and competitive environment
  • Examine key recruiting trends in Europe & Asia – exploit the patient pool and trials potential in the Southeastern Europe, Russia & Asian countries
  • Achieve competitive advantage through increased partnerships with academic centres of excellence, patient organizations & CROs
  • Gain first-hand information on PatientPartner project – how to establish partnership between stakeholders to the benefit of clinical trials and the treatment of patients in the future
  • Explore innovative methods of motivating investigators and patients
  • Understand the recent developments in the regulatory & legal environment
  • Best practices in designing a study protocol

Who should attend:
Vice Presidents, Heads, Directors, Senior Managers and Managers of: Clinical Development, Clinical Operations, Clinical Trials, Clinical Research, Patient Recruitment, Patient Retention, Site Management, Clinical Outsourcing, Sourcing Strategies, Medical Affairs, Contract Outsourcing, Clinical Strategy, Clinical Project Management, Regulatory Affairs, Clinical Research Associates, Clinical Research Organizations.

For further information and registration, please visit:
http://www.jacobfleming.com/jacob-fleming-group/conferences/life-science/6th-annual-future-of-clinical-trials?partner=worldpharmanews

About Jacob Fleming Group
Jacob Fleming Conferences are carefully designed to provide key strategic business information and the best networking opportunities for the participants. Our business to business conferences are highly interactive events with a limited number of delegates from specialized industry sectors. For each conference Jacob Fleming brings together selected senior level executives who become part of a premium community discussing the questions of the day and enjoying the value of a five star event.

Most Popular Now

Top 20 breaking World Pharma News of 2017

We are proud to announce the top 20 most popular breaking World Pharma News from 2017. Have a wonderful 2018 new(s) year filled with health, happiness, and spectacular su...

Roche and Ignyta reach definitive merger agreement

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Ignyta, Inc. (NASDAQ: RXDX) today announced they have entered into a definitive merger agreement for Roche to fully acquire Ignyta ...

Novartis advances head-to-head superiority trials …

Novartis announced today the initiation of SURPASS, a head-to-head clinical trial of Cosentyx® (secukinumab) versus proposed biosimilar adalimumab** in ankylosing spondyl...

Antidepressant may help combat the course of multi…

The antidepressant clomipramine may also alleviate symptoms of multiple sclerosis (MS), specifically in its progressive form, i.e. when it occurs without relapses or remi...

FDA updates the label of Tasigna to reflect that c…

The U.S. Food and Drug Administration today updated the product label for the cancer drug Tasigna (nilotonib) to include information for providers about how to discontinu...

Distinct human mutations can alter the effect of m…

Every person has a unique DNA sequence in their genome. Now researchers from the University of Copenhagen and the MRC Laboratory of Molecular Biology in Cambridge have tr...

Zika remains a research and public health challeng…

Since 2016, when Zika was declared by the World Health Organization as a public health emergency of international concern, the virus has become established in more than 8...

Diabetes drug 'significantly reverses memory loss…

A drug developed for diabetes could be used to treat Alzheimer's after scientists found it "significantly reversed memory loss" in mice through a triple method of action...

Try exercise to improve memory, thinking

For patients with mild cognitive impairment, don't be surprised if your health care provider prescribes exercise rather than medication. A new guideline for medical pract...

Arthritis drug could help treat advanced skin canc…

Treatment for the most deadly form of skin cancer could be more effective if combined with a well-known drug for rheumatoid arthritis, new research has shown. The study, ...

Dirt-dwelling microbe produces potential anti-mela…

A type of soil-dwelling bacterium produces molecules that induce death in melanoma cells, research at Oregon State University shows. The molecule is a secondary metabolit...

Novartis Kisqali® received FDA Breakthrough Therap…

Novartis today announced Kisqali® (ribociclib) received US Food and Drug Administration (FDA) Breakthrough Therapy designation for initial endocrine-based treatment of pr...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]